Login to Your Account

Venture Capital Sans Fundraising

Permanent Capital Focuses Safeguard's Investing Habits

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, April 23, 2012

In conjunction with Eli Lilly and Co.'s recent FDA approval of Amyvid (florbetapir), Safeguard Scientifics Inc. received a $5.6 million earn-out payment from its investment in Avid Radiopharmaceuticals Inc. before Lilly purchased the biotech.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription